Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment

Abstract

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation

“…Full details are given in the HTA report. 4 In addition to the extent of reduction in recovery time, whether sugammadex is cost-effective also depends on the value of each minute of recovery time saved (in terms of staff productivity). The economic modelling found that both reductions in recovery time and the value per minute of that time are varied across a wide range (Table 5 and Fig.…”

“…An assessment on the use of rocuronium and sugammadex compared with succinylcholine during rapid sequence induction is presented in a parallel article 3 and a full Health Technology Assessment Database (HTA) report. 4 of Abstracts of Reviews of Effect (DARE), HTA, conference proceedings, internet sites, and clinical trial registers. We also searched the manufacturer's submission to the US Food and Drug Administration (FDA) 5 and the European Medicines Agency (EMEA) assessment report for sugammadex.…”

Effects of Intracerebroventricular Sugammadex Administration on Central Nervous System in Rats

“…Results: Intracerebroventricular SUG administration did not result in any changes in behavioral status, locomotor activity or posture at any doses (2,4,8,16 and 32 mg/kg). There was no tonic clonic convulsion or seizure development following the sugammadex administration.…”

“…SUG can reverse also deep neuromuscular blockages in a short time period unlike other existing agents [1,2]. In a recent study, it was observed that administration of SUG via intravenous (IV) route does not cause any alteration in antiepileptic drug levels.…”

Paralisia residual pós-operatória

“…Due to its selectivity, sugammadex reverses the neuromuscular block induced by vecuronium and rocuronium and does not inhibit the effects of NMB belonging to the class of benzylisoquinoline alkaloids 46 (A), 47,48 (B), 49 (A).…”